Posts

Posted on

Ohio University Delivers Improved Campus Safety During COVID-19 Pandemic with the Installation of Parcel Pending by Quadient’s Smart Locker Systems

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Parcel Pending by Quadient today announced that Ohio University has installed its automated locker systems at three student mail centers on campus to provide a contactless, secure and convenient way for students and faculty to retrieve their mail and packages during the COVID-19 pandemic and beyond.

“Parcel Pending by Quadient’s smart lockers are working great and have provided, among other benefits, the added advantage of eliminating person-to-person contact between mailroom personnel and staff and faculty,” said Blaine Gabriel, director of Campus and Student Mail, Printing Services, Campus Signage and Logistics at Ohio University.

Prior to installing the smart lockers, Ohio Unversity’s mailroom staff hand-delivered mail or other items to faculty at various campus locations. Many items, such as certified mail and library materials, required the recipient’s signature. Often, more than one delivery attempt was required to obtain the signature. With Parcel Pending by Quadient’s integrated tracking system, drop-offs and pick-ups are automatically logged. By eliminating extra delivery trips and the need for human-to-human contact, the Parcel Pending by Quadient distribution system has supported safety measures during the health crisis, as well as reduced delivery time by up to an hour per day.

“These new smart lockers are saving time, increasing efficiency and adding convenience. For example, faculty no longer have to be sitting in their office to receive their deliveries. Instead, they can retrieve their mail anytime they want. Additionally, we now only have to deliver student mail and packages to our three student mail locations. This saves tremendous time for all involved,” Gabriel continued. “And, although we didn’t foresee this, smart lockers are making delivering and receiving mail safer during the pandemic.”

Electronic smart lockers provide easy-to-use interfaces for users to track assets and notify recipients of delivery in real-time. Drop-off and pick-up takes seconds, and smart locker stations can be accessed 24/7 for convenient self-service pick-up.

“We are proud to support Ohio University in increasing efficiency, convenience and safety for their students and staff in distribution of items on campus,” said Christopher O’Brien, executive vice president, Parcel Pending by Quadient. “Safe contactless delivery and distribution on college campuses have expanded well beyond mail and packages, as we are seeing universities utilize Parcel Pending by Quadient for the distribution of IT equipment like laptops, purchases from university bookstores, and the check out and returns of library materials.”

Located in Athens, Ohio University currently has 17,500 students enrolled.

About Parcel Pending by Quadient

Parcel Pending by Quadient is the leading provider of smart locker solutions for residential, commercial, retail, and university properties in the United States and Canada. With as many as 4 million packages successfully delivered monthly, Parcel Pending by Quadient offers a wide range of solutions that ensure the simple and secure delivery and retrieval of packages and online orders. With the strength of its combined power, reach, and offerings, Parcel Pending by Quadient provides state-of-the-art solutions and world-class customer service to solve the last-mile delivery challenge.

To learn more, visit parcelpending.com.

Parcel Pending by Quadient Media Contact:

Melissa Penn
[email protected]



Posted on

Synopsys Extends DesignWare Security, Processor IP Solutions to Address Safety and Security Requirements of Automotive Designs

ISO 26262 Standard-Compliant tRoot Hardware Secure Module and ARC Security Processor Add Functional Safety Features to Protect SoCs Against Data Tampering & Physical Attacks

PR Newswire

MOUNTAIN VIEW, Calif., April 14, 2021 /PRNewswire/ —

Highlights

  • ASIL B compliant tRoot Hardware Secure Module for Automotive integrates Root of Trust security solution with hardware safety mechanisms to protect against both malicious attacks and random and systematic faults
  • ASIL D compliant ARC SEM130FS Safety and Security Processor adds hardware redundancy to side-channel-attack protected processor to mitigate random hardware faults and avoid system failures
  • Both DesignWare IP products meet stringent safety process and documentation requirements, targeting a broad range of applications for ADAS, telematics, radar, V2X communications, and industrial SoCs

Synopsys, Inc. (Nasdaq: SNPS) today announced the availability of its new DesignWare® tRoot(TM) Hardware Secure Module (HSM) and ARC® SEM130FS Safety and Security Processor IP solutions with integrated functional safety features to accelerate ISO 26262 certification of automotive systems-on-chips (SoCs). The ASIL B compliant tRoot HSM for Automotive adds hardware safety mechanisms for protection against permanent, transient and latent faults to its security system that includes an ARC processor, scalable side-channel resistant cryptography, true random number generator and security-enabled external memory controllers. The ASIL D compliant ARC SEM130FS Processor adds safety-critical hardware features such as dual-core lockstep to meet stringent automotive safety requirements. Both the ARC SEM130FS Processor and tRoot HSM for Automotive are supported by comprehensive safety documentation, including failure modes, effects and diagnostic analysis (FMEDA) reports that facilitate chip- and system-level ISO 26262 ASIL B or ASIL D compliance.

“Security attacks on safety-critical ADAS, telematics, radar, V2X communications, and industrial systems are on the rise, and designers need to find ways to implement advanced security while eliminating points of failure,” said Wolfgang Ruf, product manager, semiconductors at SGS-TÜV Saar GmbH. “By extending its DesignWare tRoot HSM and ARC SEM Processor IP solutions to include functional safety mechanisms, Synopsys is enabling designers to more easily deliver SoCs that meet their customers’ ASIL requirements and secure high-value data and communication from attacks.”

The Synopsys DesignWare tRoot HSM with Root of Trust provides designers with a trusted execution environment (TEE) as part of a pre-integrated, pre-verified safety and security solution. The tRoot HSM for Automotive also incorporates safety mechanisms such as hardware redundancy, register error detection codes (EDC), memory error correction codes (ECC), watchdog timers and self-checking comparators for the entire system. In addition, the tRoot HSM for Automotive protects sensitive information and data processing in the connected car with features including secure boot, debug, firmware updates and key management.

The Synopsys DesignWare ARC SEM130FS Processor with Synopsys SecureShield™ technology helps designers to protect safety-critical systems against software, hardware and side-channel attacks with ASIL D compliance covering both random hardware faults and systematic development flow. The processor offers integrated hardware safety features including dual-core lockstep, ECC for memories and interfaces, transient fault protection for internal registers, diagnostic error injection and an integrated self-checking safety monitor. The SEM130FS processor is supported by the certified ASIL D compliant ARC MetaWare Development Toolkit for Safety to ease the development, debugging and optimization of ISO 26262-compliant software. To help designers reach target ASILs, ARC FMEDA reports are available through the VC Functional Safety Manager, and the Z01X fault simulation solution offers a complete fault model set to meet ISO 26262 fault injection testing requirements.

“As security threats for connected vehicles grow, integrating the combination of safety and security features at the SoC level helps minimize the risk of malicious attacks and data breaches in automotive systems,” said John Koeter, senior vice president of marketing and strategy for IP at Synopsys. “Synopsys’ new ARC SEM130FS and tRoot HSM for Automotive integrate both specific hardware safety features and security features to enable designers to meet ISO 26262 requirements and protect vehicle sensitive data and communications.”

Synopsys’ broad DesignWare IP portfolio includes logic libraries, embedded memories, IOs, PVT sensors, embedded test, analog IP, interface IP, security IP, embedded processors and subsystems. To accelerate prototyping, software development and integration of IP into SoCs, Synopsys’ IP Accelerated initiative offers IP prototyping kits, IP software development kits and IP subsystems. Extensive investment in IP quality and comprehensive technical support enable designers to reduce integration risk and accelerate time-to-market. For more information, please visit https://www.synopsys.com/designware.

Availability & Additional Resources

The DesignWare ARC SEM130FS Processor is scheduled to be available in Q2 2021 and DesignWare tRoot HSM for Automotive IP is scheduled to be available in Q3 2021.

Assessment information:

  • The ASIL B and ASIL D compliant ARC SEM130FS Processor is developed and assessed specifically to address ASIL B and ASIL D random hardware faults and ASIL D systematic faults.
  • The ASIL B compliant tRoot HSM for Automotive is developed and assessed specifically for ASIL B random hardware faults and ASIL D systematic faults.
  • The Certified ASIL D compliant ARC MetaWare Development Toolkit for Safety is certified as ASIL D Compliant according to ISO 26262-8 2018 as suitable for the development of safety related software up to ASIL D.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As an S&P 500 company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and offers the industry’s broadest portfolio of application security testing tools and services. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing more secure, high-quality code, Synopsys has the solutions needed to deliver innovative products. Learn more at www.synopsys.com. 

Editorial Contacts:

Simone Souza

Synopsys, Inc.
650-584-6454
[email protected] 

Cision View original content:http://www.prnewswire.com/news-releases/synopsys-extends-designware-security-processor-ip-solutions-to-address-safety-and-security-requirements-of-automotive-designs-301268733.html

SOURCE Synopsys, Inc.

Posted on

SinglePoint to Present at the Benzinga Cleantech Small Cap Conference

– Live video presentation followed by interactive Q&A with President of SinglePoint, Wil Ralston on Thursday, April 22nd

PR Newswire

PHOENIX, April 14, 2021 /PRNewswire/ — SinglePoint Inc. (OTC: SING) (“SinglePoint” or the “Company”), a company focused on providing renewable energy solutions and energy-efficient applications to drive better health and living, today announced that Wil Ralston, President of SinglePoint will present at the Benzinga Cleantech Small Cap Conference on Thursday April 22nd at 9:30 AM ET.

As part of the presentation, Mr. Ralston will provide a corporate overview and discuss how SinglePoint is transforming the traditional solar energy model, building, providing renewable energy solutions and working to become the single point for a customer’s energy and efficiency needs, to drive cleaner healthier living through environmental improvement. Following the presentation, registered attendees are invited to participate in an interactive question and answer session.

In addition, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

To access the live presentation and schedule a virtual one-on-one meeting, qualified members of the investment community are invited to register for the event here: www.benzinga.com/events/small-cap/clean-tech/

About the Benzinga Cleantech Small Cap Conference

The Benzinga Cleantech Small Cap Conference bridges the gap between cleantech companies, investors, and traders. Discover the companies in the cleantech industry who are moving the world forward through accessible green energy, energy efficiency, and innovative sustainability solutions.

For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/clean-tech/

About SinglePoint Inc.

SinglePoint Inc. is a renewable energy and sustainable lifestyle company focused on providing environmentally friendly energy efficiencies and healthy living solutions. SinglePoint is initially focused on building the largest network of renewable energy solutions and modernizing the traditional solar and energy storage model. The Company is also actively exploring future growth opportunities in air purification, electric vehicle charging, solar as a subscription service, and additional energy efficiencies and appliances that enhance sustainability and a healthier life. For more information, visit the Company’s website (www.singlepoint.com) and connect on LinkedIn and Twitter.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, the use of proceed, anticipated growth and future expansion, are forward-looking statements that involve risks and uncertainties.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Investor Contact: 

JTC Team, LLC
Jenene Thomas
833-475-8247
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/singlepoint-to-present-at-the-benzinga-cleantech-small-cap-conference-301268295.html

SOURCE SinglePoint Inc.

Posted on

Gooten Names BigCommerce its First eCommerce Preferred Provider

The exclusive partnership allows eCommerce merchants to quickly and easily access the benefits of on-demand manufacturing and scale their businesses

PR Newswire

NEW YORK, April 14, 2021 /PRNewswire/ — Gooten today named BigCommerce its first eCommerce Preferred Partner, giving Gooten’s online merchants one-step integration with the leading software-as-a-service (SaaS) platform. As part of this partnership, more than 60,000 BigCommerce customers will also gain access to Gooten’s on-demand manufacturing supply chain.

As the eCommerce landscape experiences unparalleled growth, this partnership could not come at a better time.

As a globally distributed on-demand production and logistics company, Gooten is transforming the way eCommerce businesses manufacture and fulfill products. Gooten provides brands with tailored solutions that allow them to create personalized products for their consumers, expand or diversify their current merch and product lines and move a portion or even all of their bulk inventory to a more sustainable on-demand manufacturing model. As of today, Gooten merchants and brands can quickly integrate with BigCommerce’s enterprise-grade functionality, customization and performance to help them scale their stores.

“BigCommerce is a globally acclaimed eCommerce platform committed to advancing the growth of its merchants. With a similar vision at Gooten, we are excited to partner with them to extend our full suite of out-of-the-box enterprise supply chain solutions for on-demand manufacturing,” said Brian Rainey, CEO of Gooten. “BigCommerce’s ability to provide flexible eCommerce technology combined with Gooten’s transformational approach to order management, on-demand production and fulfillment will allow our partners to scale their online stores seamlessly. As the eCommerce landscape continues to experience unparalleled growth, this partnership could not come at a better time.”

BigCommerce Enterprise offers valuable features and functionality built for enterprise businesses and shares Gooten’s deep commitment to customer service and account management.

“Our partnership with Gooten further illustrates our commitment to providing merchants access to the highest-caliber technologies and service providers available in the industry,” said Russell Klein, chief commercial officer for BigCommerce. “Gooten shares our desire to help merchants sell more and grow faster to maximize success, and we look forward to working together to mutually support customers.”

For more information, please visit https://www.gooten.com/bigcommerce.

About Gooten
Gooten operates a smart supply chain for brands looking to optimize their eCommerce business with on-demand manufacturing. It combines proprietary technology and operational expertise with a global network of 30+ best-in-class manufacturing partners. This infrastructure allows Gooten to fulfill orders more efficiently, sustainably, and at a competitive rate. Gooten’s manufacturing-on-demand model makes it possible for eCommerce brands to sell high-quality products without holding any inventory. Founded in 2015 and already profitable, Gooten is based in New York City. For more information, please visit http://www.gooten.com

About BigCommerce
BigCommerce (Nasdaq: BIGC) is a leading software-as-a-service (SaaS) ecommerce platform that empowers merchants of all sizes to build, innovate and grow their businesses online. As a leading open SaaS solution, BigCommerce provides merchants sophisticated enterprise-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2B and B2C companies across 120 countries and numerous industries use BigCommerce to create beautiful, engaging online stores, including Ben & Jerry’s, Skullcandy, Sony and Woolrich. Headquartered in Austin, BigCommerce has offices in San Francisco, Sydney and London. Learn more at www.bigcommerce.com.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Media Contact:

Becky Frost


[email protected]
 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/gooten-names-bigcommerce-its-first-ecommerce-preferred-provider-301268714.html

SOURCE Gooten

Posted on

Validere Announces 900% Growth for US Operations in the First Quarter of 2021

Demand for Real-Time Oil and Gas Data Intelligence, ESG Mandates Fueling Rapid Expansion

Houston and Calgary, April 14, 2021 (GLOBE NEWSWIRE) — Validere, a leading data intelligence platform for oil and gas product quality, announced its US operations grew by more than 900% quarter over quarter in Q1 of 2021. Validere’s surging demand reflects the substantial market opportunity and demand for actionable, real-time oil and gas data and predictive insights at the molecular level, that now includes ESG attributes.

After entering the U.S. market in 2020, Validere accelerated client growth, made strategic executive appointments, acquired a new office in Houston’s “The Cannon” technology hub and expanded its ESG focus. 

To support escalating customer demand, Validere’s headcount tripled in 2020 despite the pandemic. Validere relocated its U.S. headquarters to Houston’s technology hub to support the growth, and in the first quarter of 2021, appointed Kayla Ball as Senior Vice President, Product. Ben Tao was named Senior Vice President of Marketing, Jana Shelford was named Vice President of Talent and Culture, and Jesse Shouldice was appointed Vice President of Business Development. The new executive appointments mark Validere’s focus on bringing together the brightest talent to solve the industry’s most complex challenges.

“Some of the brightest technology and industry talent across North America has joined Validere’s mission to bring operational, commercial, and environmental efficiency to the oil and gas industry,” said Nouman Ahmad, Validere’s CEO. “Validere is proud to power more than 50 of North America’s leading energy companies with real-time intelligence and insights to identify operational efficiencies and action the highest-margin commercial decisions, while also supporting ESG mandates.” 

Kayla Ball is a respected leader with an in-depth knowledge of the industry and customer needs. In her most recent role as Managing Director of Commercial Strategy at Enverus, Kayla championed the customer’s voice to determine product gaps and drive product strategy. Kayla has also served as IHS Markit’s Portfolio Strategic Director, responsible for leading the product management team with end-to-end product innovation processes throughout the product life cycle of the upstream energy portfolio.

Ben Tao is a seasoned technology marketing leader with more than 20 years of experience in brand, product marketing, digital marketing, demand generation, and customer experience.  Previously, Ben was Forcepoint’s Vice President of Corporate Marketing where he led the repositioning of its brand into an enterprise-class, SaaS cybersecurity vendor focused on human-centric cybersecurity. He also directed marketing teams across the IT and analytics markets at IBM, Dell, and Solarwinds.

Jesse Shouldice spent 17 years in the energy industry in investment banking and building businesses within commodity derivatives. Prior to Validere, Jesse served as VP of Global Commodities at J.P. Morgan, rebuilding its Canadian financial derivatives business. He held leadership roles at Credit Suisse, Citi, and Goldman Sachs.

Jana Shelford has focused her career on helping oil and gas companies to differentiate themselves with human capital. In her previous role as HR Director with RS Energy Group, she fueled its high-performance culture as the business scaled to achieve every stretch goal.

###

About Validere

Validere is a data-intelligence platform for oil and gas product quality. The first and only software that provides real-time visibility into the true composition and quality of oil and gas, Validere’s insights and team of experts enable industry participants to identify operational efficiencies and the highest-margin marketing and supply decisions. Validere is transforming the world’s largest supply chain by making critical product-quality data accessible and actionable. More than 50 of North America’s leading energy companies rely on Validere’s insights to reduce waste and emissions and enhance operational and trading margins.



Kristen Quinn
Paige PR
[email protected]

Posted on

St. Joseph’s Healthcare Hamilton Selects Spok Go® to Improve Connectivity Across the Health System

St. Joseph’s Healthcare Hamilton Selects Spok Go® to Improve Connectivity Across the Health System

Canadian health system also collaborates with Spok to help optimize the Spok Go platform

SPRINGFIELD, Va.–(BUSINESS WIRE)–Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a leader in healthcare communications, announced that St. Joseph’s Healthcare Hamilton (SJHH) has selected Spok Go® to enable safe, secure digital communication across its hospital system. The cloud-native platform benefits both patients and clinicians. By improving clinical workflows, clinicians can spend more time with their patients. Additionally, St. Joseph’s Healthcare Hamilton is collaborating with Spok to help optimize Spok Go as a Clinical Innovation Partner. The Ontario hospital, which has earned a national reputation for outstanding patient care and innovative medical and surgical treatments, will modernize its systems with Spok Go, including on-call scheduling with secure messaging. The hospital is well known for excellence in respiratory care, kidney and urinary care, mental health and addictions services, surgical services, and women’s and infant care.

“St. Joe’s is already a leader in digital health record systems and digital health access for patients. Our goal is to build new digital communications to support connectivity between healthcare providers across the hospital,” said Tara Coxon, Chief Information Officer at St. Joseph’s Healthcare Hamilton. “Spok provides us with the ability to do all of this and more. We cannot wait to get started with physician on-call scheduling and look forward to multi-site communication in the future.”

This collaboration will focus on fostering clinical innovation that creates value for Spok Go and optimizes the use of Spok Go at SJHH. The organization plans to initially work closely with Spok to further optimize on-call scheduling by implementing Spok Go at its main campuses and satellite locations. In the future, the organizations will collaborate on other aspects such as critical test result reporting, codes and alerting, referral and consult management, and nurse call alerts.

“SJHH is a highly-regarded, national leader in clinical innovation and integrated patient care and we are honored that they have chosen Spok Go,” said Vincent D. Kelly, president and chief executive officer of Spok Holdings, Inc. “Our collaboration will be instrumental as we continually work to further optimize and advance Spok Go. We look forward to seeing the efficiency and reliability that our cloud-native platform can bring to SJHH, and what we will learn from this premier health system through this partnership. We believe that this is yet another proof-point of the broad acceptance our best-in-class cloud-native Spok Go platform is receiving both in the North American markets and internationally.”

Learn more about Spok Go at Spok.com/SpokGo.

About St. Joseph’s Healthcare Hamilton

St. Joseph’s Healthcare Hamilton (SJHH) is a leading research and academic health science centre located in the heart of Hamilton, Ontario. It is a pioneer of the Integrated Comprehensive Care model, a leader in patient-centred care, and a major provider of mental health and addiction services, respiratory care and kidney care, in addition to other acute care, surgical and outpatient services at its three distinct sites. St. Joseph’s Healthcare Hamilton, a proud member of St. Joseph’s Health System, is a teaching hospital affiliated with the world-renowned McMaster University. For more information about St. Joseph’s Healthcare Hamilton, please visit www.stjoes.ca.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Go® and Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients’ lives are at stake, Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter.

Spok is a trademark of Spok Holdings, Inc. Spok Go and Spok Care Connect are trademarks of Spok, Inc.

Katlyn Nesvold

+1 (952) 230-5584

[email protected]

KEYWORDS: United States North America Canada Virginia

INDUSTRY KEYWORDS: Mobile/Wireless Technology Nursing Hospitals Security Telecommunications Software Networks Health Data Management

MEDIA:

Logo
Logo
Posted on

ADAMA Provides Net Income Estimate for Q1 2021

Robust business growth expected to drive higher reported net profit

PR Newswire

TEL AVIV, Israel and BEIJING, April 14, 2021 /PRNewswire/ — ADAMA Ltd. (the “Company”) (SZSE: 000553), today provided an estimate regarding its financial performance for the first quarter of 2021.

Sales

ADAMA is expecting to report record-high first quarter sales, with estimated top-line growth of more than 13% (6% in RMB terms), driven by continued robust volume growth in almost all key regions.

The Company is expecting to record strong growth in Asia Pacific, both in China and beyond. In China, ADAMA saw significant growth in the quarter both from its branded, formulated portfolio, which was driven by higher cereal demand due to an increase in field crop planted areas and an early start to the Q2 season, as well as from its sales of raw materials and intermediates. Sales in the country were further bolstered by the inclusion of the Company’s recent acquisition of Jiangsu Huifeng’s domestic commercial crop protection business.

In the rest of APAC, the Company benefited from favorable seasonal conditions to deliver strong growth, despite a slower recovery from COVID-19 challenges in Asia.

Continued positive weather conditions also supported robust growth in the India, Middle-East & Africa region.

In North America, a strong performance from the Company’s Consumer and Professional business drove growth in the region, benefiting from the reopening of the economy after COVID-19 related restrictions in 2020, and more than offset a somewhat softer performance in the US crop protection business.

The Company continues its growth trajectory in Latin America, driven by solid volume growth and good performance from recent product launches in the region, and despite somewhat lower sales in Brazil following a strong end to the fourth quarter there last year.  

Sales in Europe are expected to be somewhat lower in the quarter, with growth in the south, where favorable market conditions drove good demand, being outweighed by a slow start to the season in the north and east, especially when compared to Q1 2020 which saw strong orders from distribution in anticipation of the COVID-related shutdowns that soon followed.

Net Income

Reported Net Income in the quarter is expected to be significantly improved against the loss recorded in the corresponding period last year. This improvement is driven by the strong sales growth, resulting in higher reported operating income, and is expected to be achieved despite somewhat higher financial expenses expected in the quarter.


Reported
 Net Income


Estimated Q1 2021


Q1 2020

Net income attributable to shareholders (USD millions)

22 – 32

-2

Earnings per share (USD)

0.0094 – 0.0137

-0.0010

Net income attributable to shareholders (RMB millions)

143 – 207

-17

Earnings per share (RMB)

0.0612 – 0.0890

-0.0068

The Company’s Reported Net Income in the first quarter of 2021 is expected to reflect around $32 million (Q1 2020: $44 million) of net expenses in respect of certain non-operational, mostly non-cash items, including mainly:

  i.  Approximately $15 million in Q1 2021 (Q1 2020: $15 million) of Relocation & Upgrade-related costs, including mainly (a) higher procurement costs incurred as the Company continued to fulfill demand for its products in order to protect its market position, through replacement sourcing at significantly higher costs from third-party suppliers; and (b) idleness charges largely related to suspensions at the facilities being relocated;

  ii.  Approximately $8 million in Q1 2021 (Q1 2020: $8 million) in non-cash amortization charges in respect of Transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition;

  iii.  Approximately $3 million in Q1 2021 (Q1 2020: $2 million) in charges related mainly to the non-cash amortization of intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired, as well as other M&A-related costs.

Excluding the impact of the abovementioned non-operational, mostly non-cash items, the Company is expecting to deliver the following Adjusted Net Income:


Adjusted
 Net Income


Estimated Q1 2021


Q1 2020

Net income attributable to shareholders (USD millions)

54 – 64

41

Earnings per share (USD)

0.0231 – 0.0274

0.0170

Net income attributable to shareholders (RMB millions)

349 – 414

289

Earnings per share (RMB)

0.1499 – 0.1777

0.1182

Note: The Q1 2020 Adjusted Net Income shown above has been amended from that presented at the time to include additional adjustments in order to consistently reflect largely the treatment of Relocation & Upgrade Program-related costs amongst other adjustments that the Company has deemed non-operational and one-time in nature.

These estimations are preliminary and have not been audited or reviewed by the Company’s auditors. These estimations may change, inter alia, as a result of the further processing and analysis of the financial data that the Company will perform for the preparation of its financial statements which will be released on April 28, 2021.

Investors are reminded to exercise caution when making investment decisions.

About ADAMA

ADAMA Ltd. (SZSE: 200553) is a global leader in crop protection, providing solutions to farmers across the world to combat weeds, insects and disease. ADAMA has one of the widest and most diverse portfolios of active ingredients in the world, state-of-the art R&D, manufacturing and formulation facilities, together with a culture that empowers our people in markets around the world to listen to farmers and ideate from the field. This uniquely positions ADAMA to offer a vast array of distinctive mixtures, formulations and high-quality differentiated products, delivering solutions that meet local farmer and customer needs in over 100 countries globally. For more information, visit us at www.ADAMA.com and follow us on Twitter® at @ADAMAAgri.

Logo – https://mma.prnewswire.com/media/799829/Adama_Agricultural_Solutions_Logo.jpg

Contact

Ben Cohen

Global Investor Relations
Email: [email protected]

Zhujun Wang

China Investor Relations
Email: [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/adama-provides-net-income-estimate-for-q1-2021-301268823.html

SOURCE ADAMA Ltd.

Posted on

New Research Finds That 72% of US Digital Advertisers Believe CTV Reaches Audiences More Effectively Than Linear TV

Tremor Video study uncovers advertisers’ attitudes and perceptions about CTV’s expanding role in brand marketing strategies

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) — Tremor Video, a leading programmatic video platform, and leading ad platform Unruly, in partnership with MTM Global, today announced the findings from a study focusing on how connected TV (CTV) is used by advertisers and key areas for development. The research reveals that nearly three-quarters (72%) of US digital advertising professionals believe that CTV reaches target audiences more effectively than linear TV, with 85% making CTV a key part of their video strategy. The research, conducted in December 2020, included surveys and in-depth interviews with brand marketers and media agency professionals.

“As a result of consumers increasingly engaging with CTV content and at notably higher rates since the COVID-19 outbreak last year, we are seeing more and more advertisers making CTV a prominent fixture in their strategic planning,” said Justin Chadwick, VP Marketing, Tremor Video. “We believe this growth trend is likely to continue, as our research suggests that advertisers perceive CTV not only as an essential component of their media mix, but also as an effective one in terms of fulfilling their key business objectives.”

Tremor Video and Unruly conducted this research to learn more about how advertisers are currently thinking about the opportunities, challenges and effectiveness of the fast-emerging CTV medium, within the broader context of their marketing mix. It also offers brands and media agencies actionable insights into how best to leverage CTV. Key findings include:

  • 85% of those surveyed say CTV is a key part of their video advertising strategy (90% of media agencies and 75% of brand advertisers)
  • 90% of respondents plan to increase their 2021 CTV budgets, with an average increase of 53%
  • 56% of media agency respondents and 37% of brand advertiser respondents predict that more than half of their video budgets will be spent on CTV in 2021
  • 75% of respondents believe that CTV has been more important to their business’ marketing success during the COVID-19 pandemic
  • 94% of respondents believe that CTV campaigns successfully meet their marketing objectives

Since the pandemic’s onset, Tremor Video has observed an acceleration in the shift from linear TV to CTV, as more viewers have turned to Ad-Supported Video on Demand (AVOD) in particular for their dynamic streaming content. According to Nielsen, roughly three times as many Americans are now embracing AVOD as compared to before the pandemic.

Moreover, Tremor’s research suggests that CTV is more effective in driving consumer actions than linear TV. According to a recent Tremor study, consumers exposed to CTV advertising are 71% more likely to advocate and tell a friend about a brand than consumers exposed to linear TV, with 52% more likely to buy a product and 45% more likely to visit a store or product website.

“With CTV penetration growing in such rapid ways, with 4 out of 5 households streaming their content on large TV devices, we believe CTV is one of the most important channels in our media mix,” said Shana Kohen, SVP, Group Account Director, Carat. “More time spent from viewers on CTV means more inventory. This coupled with the technological improvements such as more targeting and identity options, ability to bring data in, cross-device measurement—all of this helps ad spend flow to CTV.”

CTV is a significant growth engine for Tremor International, with Tremor Video and Unruly’s parent company recently reporting 127% revenue growth in the CTV space in Q4 2020 compared to Q4 2019. The company has also reported that its performance during the first quarter of 2021 is significantly ahead of the same period in 2020 and it expects trading for the year to be ahead of management expectations. This positive momentum is underpinned by the successful execution of Tremor’s strategy, which focuses on video and data, with the company’s core solutions of CTV, private marketplaces (PMPs), and its self-service platform.

Scheduled to launch in late May 2021, Tremor Video’s new TV Intelligence offering will leverage its proven experience in CTV and addressable TV retargeting to allow advertisers to reach the most relevant consumers with precision, using a wide breadth and depth of audience data assets.

For more information and to download the full report summary, click here.

Methodology

Tremor Video, Unruly, and MTM Global surveyed around 200 US and UK ad professionals for the study. All respondents who took part in the study work for either a brand, media agency, DSP or trading desk and have experience planning or buying TV or online digital advertising over the last 12 months. The survey was conducted in December 2020 alongside in-depth interviews with digital media professionals. The UK research findings can be found here.

About Tremor International

Tremor International Ltd is a global leader in advertising technologies, it has three core capabilities: Video, Data and CTV, and our unique approach is centered on offering a full stack end-to-end platform which we believe provides the company with a major advantage in the marketplace. 

Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of innovative video technology combined with advanced audience data and captivating creative content. Tremor Video is one of the largest and most innovative video advertising companies in North America and globally, with offerings in CTV, in-stream, out-stream and in-app. 

The media side of Tremor, Unruly, drives real business outcomes in multiscreen advertising. Its highly ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners. Tremor has a meaningful number of direct integrations with publishers, unique demand relationships with the world’s biggest advertisers and privileged access to News Corp inventory. Unruly works with 95% of the Ad Age 100 and 82% of video views are delivered across Comscore 1,000 sites.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by the Company at the time these statements were made.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable at the time made, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements.

The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact

Matt Caldecutt
[email protected]
347-687-3721



Posted on

BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)

The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction

CRESSKILL, N.J. and JERUSALEM, Israel, April 14, 2021 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced today that 100,000 patients have been treated globally with Deep transcranial magnetic stimulation (Deep TMS).

The noninvasive therapy administers magnetic pulses through a proprietary H-coil to target structures of the brain associated with mental health conditions. The technology received FDA clearance for the treatment of major depressive disorder (MDD) in 2013 and for the treatment of obsessive-compulsive disorder (OCD) in 2018. Most recently, the technology was FDA cleared as an aid for short-term smoking cessation.

“As scientific founders of BrainsWay, it is rewarding to see the Company achieve this milestone and to witness the positive impact this groundbreaking technology has had on so many patients and families,” said Prof. Abraham Zangen, Co-Founder and Board Director of BrainsWay, and Yiftach Roth, Ph.D., Co-Founder and Chief Scientific Officer of BrainsWay. “This novel technology can help millions of patients in the coming years, and we are honored to be part of providing successful and noninvasive mental health solutions to those who need them most.”

BrainsWay’s Deep TMS has been investigated in more than 30 randomized clinical trials worldwide, with additional studies ongoing or planned. Conducted primarily in the outpatient setting, patients can return to normal activities immediately following the treatment session. By penetrating deeper and broader than traditional figure-8 TMS devices, Deep TMS has demonstrated versatility in addressing a range of disorders by safely targeting and stimulating deeper and broader brain regions.  

“When I first had the opportunity to evaluate this technology, it was clear that this was a unique solution with the ability to transform lives,” said David Zacut, MD, Founder and Chairman of BrainsWay. “At that time, TMS technology had not yet been widely adopted clinically, but it showed substantial promise to advance the field of neuroscience. It has been a pleasure seeing how far the Company has grown and progressed the field over the past two decades.”

There are more than 600 BrainsWay Deep TMS Systems installed in private clinics, outpatient facilities, and hospitals globally. For more information around provider locations visit brainsway.com/find-a-provider.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.  These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Additionally, the claims contained herein are based on various internal data and assumptions which may be subject to differing interpretation, analysis, and further assessment. The following factors, among others, could cause actual results to differ materially from those described herein: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; inadequacy and/or inconsistency between different tracking processes; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

Contact:

BrainsWay:
Hadar Levy
SVP and General Manager
[email protected]

Media Contact:
Will Johnson
(201) 465-8019
[email protected]



Posted on

Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will host a key opinion leader (KOL) call on novel biomarkers in identifying appropriate responders to immune checkpoint inhibitors on Monday, April 19, 2021 at 11:30am Eastern Time.

The event will feature a presentation by KOLs David Gandara, MD, UC Davis Comprehensive Cancer Center, and Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center, who will present an overview of the use and limitations of currently clinically available biomarkers, such as PD-L1 and tumor mutational burden (TMB), in identifying responders to immunotherapies, specifically immune checkpoint inhibitors (ICI) that are FDA-approved for a broad range of solid tumors. New data will also be discussed, presented for the first time during an oral symposium at the 2021 American Association for Cancer Research (AACR) Annual Meeting, showing that DetermaIO™, a 27-gene test that assesses the tumor microenvironment to identify immunotherapy responders, has strong performance in identifying responders to atezolizumab in bladder cancer, as measured by overall survival rates in DetermaIO-positive patients who received ICI. This adds to previously presented data in non-small cell lung cancer and triple-negative breast cancer that demonstrates incremental utility beyond PD-L1 and TMB in identifying responders to all currently approved ICIs. Evidence now presented for three different cancers suggests a potential pan-cancer application for the test.

Drs. Parikh and Gandara will be available to answer questions following the formal presentations.

To register for the call, please click here.

Mamta Parikh, MD, MS is a medical oncologist and assistant professor at the University of California, Davis. She specializes in the medical treatment of genitourinary malignancies including kidney/renal cell, bladder, prostate, ureteral cancers, and germ cell tumor cancers. Her clinical research interests focus on prostate, kidney, and bladder cancer. She is the principal investigator on numerous clinical trials, is the national principal investigator on an NCI-sponsored trial of a novel ATR inhibitor in combination with chemotherapy in advanced solid tumors, and collaborates with basic researchers on translational clinical research projects. She is an active member of the California Cancer Consortium and the Southwest Oncology Group.

After a successful career as a medicinal chemist, Dr. Parikh received her medical degree from the University of California, Davis, and completed her residency and an oncology fellowship at UC Davis as well. She was the recipient of the Joseph Sullivan Research Award in 2016 and is currently a recipient of the NCI-sponsored Paul Calabresi K12 Career Development Award.
        
David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine is the Senior Advisor to the Director and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is an internationally known clinician-scientist and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trial through the Southwest Oncology Group (SWOG), and translational science projects. He is the clinical director for a National Cancer Institute (NCI) award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee, and a member and founding co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts, and editorials. He is editor-in-chief of the journal Clinical Lung Cancer. He served as president of the International Association for the Study of Lung Cancer (IASLC) from 2009-2011 and served as treasurer from 2013-2017. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). Most recently, he serves as clinical director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer and is UCD Comprehensive Cancer Center’s principal investigator for the Stand Up To Cancer (SU2C) dream team in KRAS-mutated lung cancer.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the Company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation. TheraSure is a trademark of Chronix Biomedical Inc.

Oncocyte Forward Looking Statements. Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These include statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]